Taskforce on Innovative International Financing for Health Systems: what next?

McCoy, David; Brikci, Nouria

doi:10.2471/blt.09.074419

Cited by 22 publications

(14 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…439 The opportunity to link revenue generation to a global redistributive and environmental agenda should be sought via taxes on carbon, luxury items, or capital flow, and leveraging an increased domestic return on the natural resources and primary commodities of poor countries. 440 Other financing mechanisms including global health bonds, debt-conversion instruments, market commitment instruments, social and development impact bonds, and global solidarity taxes and levies need to be invoked. Opportunity can be seized in the current political momentum within the G20 countries that is in favour of increased levies on currency transactions and additional financial transaction taxes that could be used to regulate the global financial system.…”

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

“…Opportunity can be seized in the current political momentum within the G20 countries that is in favour of increased levies on currency transactions and additional financial transaction taxes that could be used to regulate the global financial system. 440 The agenda of expanding the domestic resource base of low-income countries is also important for generating finances for health-care programmes. Many low-income countries could increase domestic public finance by reducing capital flight, promoting more effective tax policy, and improving their tax collection systems.…”

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

See 1 more Smart Citation

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Sarin

Kumar

Eslam

et al. 2020

The Lancet Gastroenterology & Hepatology

390

303

View full text Add to dashboard Cite

The Asia-Pacific region is home to more than half of the global population and accounted for 62·6% of global deaths due to liver diseases in 2015. 54·3% of global deaths due to cirrhosis, 72·7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute viral hepatitis occurred in this region in 2015. Chronic hepatitis B virus (HBV) infection caused more than half of the deaths due to cirrhosis in the region, followed by alcohol consumption (20·8%), non-alcoholic fatty liver disease (NAFLD; 12·1%), and chronic infection with hepatitis C virus (HCV; 15·7%). In 2015, HBV accounted for about half the cases of hepatocellular carcinoma in the region. Preventive strategies for viral hepatitis-related liver disease include increasing access to clean drinking water and sanitation. HBV vaccination programmes for neonates have been implemented by all countries, although birthdose coverage is extremely suboptimal in some. Availability of screening tests for blood and tissue, donor recall policies, and harm reduction strategies are in their initial stages in most countries. Many governments have put HBV and HCV drugs on their essential medicines lists and the availability of generic versions of these drugs has reduced costs. Efforts to eliminate viral hepatitis as a public health threat, together with the rapid increase in per-capita alcohol consumption in countries and the epidemic of obesity, are expected to change the spectrum of liver diseases in the Asia-Pacific region in the near future. The increasing burden of alcohol-related liver diseases can be contained through government policies to limit consumption and promote less harmful patterns of alcohol use, which are in place in some countries but need to be enforced more strictly. Steps are needed to control obesity and NAFLD, including policies to promote healthy lifestyles and regulate the food industry. Inadequate infrastructure and insufficient health-care personnel trained in liver diseases are issues that also need to be addressed in the Asia-Pacific region. The policy response of most governments to liver diseases has thus far been inadequate and poorly funded. There must be a renewed focus on prevention, early detection, timely referral, and research into the best means to introduce and improve health interventions to reduce the burden of liver diseases in the Asia-Pacific region. 168 www.thelancet.com/gastrohep Vol 5 February 2020The Lancet Gastroenterology & Hepatology Commission accounted for 108 276 (8·2%) of the total liver-related deaths in the region in 2015, compared with 929 (1·2%) of 72 437 in the USA and 4032 (0·3%) of 197 179 in Europe. Deaths in the Asia-Pacific region represented three-quarters of the global total number of deaths due to acute viral hepatitis. In 2015, the region accounted for three-quarters of the global total number of deaths related to acute HBV, almost two-thirds of those due to acute hepatitis A infection, and almost 80% of those due to acute hepatitis E infection. Of all deaths du...

show abstract

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Sarin

Kumar

Eslam

et al. 2020

The Lancet Gastroenterology & Hepatology

390

303

View full text Add to dashboard Cite

show abstract

“…They claim that it has helped maintain momentum for increased international financial support for health in low-income countries at a time of the financial crisis. In response, McCoy & Brikci 14 argue that the Taskforce report was disappointing. It gave only lukewarm support to a financial transactions levy, an option targeting the banking sector, while supporting consumer taxes affecting the poorer population groups.…”

mentioning

confidence: 99%

Health systems financing and the path to universal coverage

Evans

Etienne

2010

Bull. World Health Organ.

385

186

View full text Add to dashboard Cite

“…The debate about ''access'' has been widely marked by the quest for access to medicines and incentives for the pharmaceutical industry to engage in the development of new drugs and vaccines [33]. Market-based financing mechanisms have been launched (such as the Advanced Market Commitment, the GAVI Alliance's International Financial Facility for Immunizations, or UNITAID's levy on airplane tickets) and narrowly targeted to develop and/or buy drugs or vaccines [34], possibly rewarding companies with prices much higher than needed when risks and costs of R&D to develop medicines for global health problems are correctly estimated [35].…”

Section: Medical Productsmentioning

confidence: 99%

Understanding the Impact of Global Trade Liberalization on Health Systems Pursuing Universal Health Coverage

Missoni

2013

Value in Health

View full text Add to dashboard Cite

In the context of reemerging universalistic approaches to health care, the objective of this article was to contribute to the discussion by highlighting the potential influence of global trade liberalization on the balance between health demand and the capacity of health systems pursuing universal health coverage (UHC) to supply adequate health care. Being identified as a defining feature of globalization affecting health, trade liberalization is analyzed as a complex and multidimensional influence on the implementation of UHC. The analysis adopts a systems-thinking approach and refers to the six building blocks of World Health Organization's current "framework for action," emphasizing their interconnectedness. While offering new opportunities to increase access to health information and care, in the absence of global governance mechanisms ensuring adequate health protection and promotion, global trade tends to have negative effects on health systems' capacity to ensure UHC, both by causing higher demand and by interfering with the interconnected functioning of health systems' building blocks. The prevention of such an impact and the effective implementation of UHC would highly benefit from a more consistent commitment and stronger leadership by the World Health Organization in protecting health in global policymaking fora in all sectors.

show abstract

Taskforce on Innovative International Financing for Health Systems: what next?

Cited by 22 publications

References 1 publication

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Health systems financing and the path to universal coverage

Understanding the Impact of Global Trade Liberalization on Health Systems Pursuing Universal Health Coverage

Contact Info

Product

Resources

About